ECYT


Biotech Universe: Mizuho Expects Mylan N.V. (MYL) To Rally, Endocyte, Inc. (ECYT) Brings Wedbush Over To The Bulls

Analysts weigh in with confidence on two biotech stocks blasting through the roof this week.

“Izzy” Englander Gets More Confident on Endocyte, Inc. (ECYT), Ducks Out from Valeant Pharmaceuticals Intl Inc (VRX)

The hedge fund guru’s Q2 moves added ECYT gains to his pocket while saving him greater losses in VRX.

Endocyte, Inc. (ECYT) Shares Are Exploding 90% – Here’s Why

It’s a very rewarding trading day for investors in Endocyte, Inc. (NASDAQ:ECYT) with shares up nearly 90%, making the stock Wall Street’s bull …

Endocyte, Inc. (ECYT): Cowen’s Downgrade Adds Fuel to the Fire

In a research report released Friday, Cowen analyst Boris Peaker downgraded shares of Endocyte, Inc. (NASDAQ:ECYT) from Outperform to Market Perform, after the drug maker …

Endocyte, Inc. (ECYT) Releases Updates on Clinical Development Programs

Endocyte, Inc. (NASDAQ:ECYT) announced updates on clinical development for EC1456, its folate receptor-targeted tubulysin cancer therapy, and EC1169, its prostate-specific membrane antigen targeted …

Company Update (NASDAQ:ECYT): Endocyte, Inc. and Seattle Children’s Research Institute to Collaborate

Endocyte, Inc. (NASDAQ:ECYT) announced their plan to collaborate with Seattle Children’s Research Institute and Dr.

Company Update (NASDAQ:ECYT): Endocyte, Inc. Presents Data on Two Lead Clinical Programs at ESMO 2016 Congress

Endocyte, Inc. (NASDAQ:ECYT) presented poster updates on its two lead clinical programs at the ESMO 2016 Congress, being held in Copenhagen, Denmark October 7-11, …

Stock Update (NASDAQ:ECYT): Endocyte, Inc. Appoints Mike Sherman as President and Chief Executive Officer

Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that Mike …

Company Update (NASDAQ:ECYT): Endocyte, Inc. Reports First Quarter 2016 Financial Results

Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts